IASLC Lung Cancer News (ILCN), March 2022
ILCN | English
Image For Activity Cover
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered
Table of Contents
  • The FDA Explained: An Interview with Dr. Harpreet Singh
  • A New Standard of Care in EGFR-Positive NSCLC Unresponsive to TKIs?
  • The OncoKB Precision Oncology Knowledge Base: A Q&A with Dr. Debyani Chakravarty
  • Targeting Angiogenesis in Mesothelioma: Insights From MAPS and RAMES
  • US FDA greenlights nivolumab for use before surgery for NSCLC
  • Low-Dose CT, ctDNA May Partner for Lung Cancer Detection
  • Award Lecture Highlights Tumor Evolution Through Liquid Biopsy
  • Patient Perspective: Anxiety Follows Abrupt Departure From Clinical Trial
  • Determining the Most Effective Chemotherapy Regimen in Patients With Advanced KRAS-Mutated NSCLC: the NVALT22 study
  • Novel Targets and Therapies: KEAP1- and NFE2L2-Mutant Squamous Cell Lung Cancer
  • Management of Recurrences after Stereotactic Ablative Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer
  • Role of Liquid Biopsy in the Clinic Growing
  • Need for Molecular Nursing Increasing
IASLC Lung Cancer News (ILCN) is the offical news source of the only global association dedicated to the multidisciplinary study of lung cancer, published bimonthly by the International Association for the Study of Lung Cancer (IASLC). 

Click here to link to Submission Guidelines.
Powered By